Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Biogen Phase 1
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5)
•••
Comment by Fryinpanon Aug 30, 2021 7:46am
143 Views
Post# 33780656

RE:Biogen Phase 1

RE:Biogen Phase 1Phase one actually ended in 2012. Phase 1b ended in March 2015.  "Biogen brought aducanumab to a phase 1 trial in 2011 whereby giving a single ascending dose by intravenous infusion to participants with mild-to-moderate AD demonstrated a good safety profile when compared to those receiving the placebo dose. Biogen next conducted a phase 1b randomized, double-blind, placebo-controlled, multiple-dose trial evaluating aducanumab at 1, 3, 6, and 10 mg/kg in participants with prodromal (amyloid-positive by PET but asymptomatic) and mild AD. The promising results from this trial were presented at two conferences in 2015 (Alzheimer’s & Parkinson’s Diseases Congress [AD/PD] and AAIC) and demonstrated dramatic dose- and time-dependent reduction of amyloid plaque burden over 54 weeks of treatment, as measured by amyloid PET". 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities